Catalyst Dossier · compiled by CeliA 🧫
Marker Therapeutics, Inc. (MRKR)
Pharmaceutical Preparations · market cap $17M · as of 2026-07-19
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
2
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Marker Therapeutics (MRKR) is a micro-cap clinical-stage biotech with a $22M market cap, 5 employees, and a single disclosed pipeline asset: a low-dose folate receptor alpha (FRα) vaccine in Phase 2 for breast cancer. The company carries $14.9M in cash (roughly 32 months of runway at current burn) and no meaningful revenue outside of sporadic non-recurring items. The next scheduled event is an earnings release on 2026-08-13.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Low dose FRα vaccine | Phase 2 | Breast Cancer |
| TPIV200 | Phase 2 | Ovarian Cancer |
Price & technical context
3-month
-22.8%
6-month
-24.3%
12-month
-5.9%
52-wk range
$0.85–$2.19
vs 50-day MA
-16.7%
vs 200-day MA
-20.3%
Realized vol
80.6%
Max drawdown
-85.7%
Daily closes through 2026-08-11. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for MRKR (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.